ICON
ICON Public Limited Company is a global contract research organization that offers outsourced development services to the pharmaceutical, biotechnology, and medical device sectors. Established in 1990 and headquartered in Dublin, Ireland, ICON specializes in the strategic development, management, and analysis of programs that support all phases of the clinical development process, from compound selection to Phase I-IV clinical studies. The company provides a comprehensive range of services, including product development planning, clinical pharmacology, patient recruitment and retention, project management, and data management. Additionally, ICON offers ancillary services such as medical imaging, biostatistics, pharmacovigilance, and regulatory support. Its capabilities extend to adaptive and virtual trial services, as well as research trials for government agencies, making it a versatile partner for firms navigating the complexities of drug development and clinical trials.
Top Stages
21 past transactions
HumanFirst
Acquisition in 2024
HumanFirst is a developer of an AI-powered software-as-a-service platform that aims to enhance patient-centered clinical trials through the use of precision digital measures, including digital biomarkers and electronic clinical outcome assessments. The platform, recognized as the largest of its kind, provides biopharma companies with valuable insights and validated evidence data to streamline drug development processes. By facilitating the integration of digital health technologies, HumanFirst supports pharmaceutical organizations in improving research efficiency and accelerating the deployment of innovative treatments. The platform has been utilized by 22 of the 25 largest pharmaceutical companies worldwide, underscoring its significance in advancing human-centric research and development.
PRA Health Sciences
Acquisition in 2021
PRA Health Sciences, established in 1976 and headquartered in Raleigh, North Carolina, is a leading global contract research organization (CRO). It offers comprehensive outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. PRA's extensive services span clinical research, including product registration, early development, and strategic solutions, as well as data solutions such as market intelligence, consulting, and technology-enabled products. With over 17,000 employees across 90 offices in six continents, PRA has supported more than 3,800 clinical trials and contributed to the approval of over 85 products since 2000. The company is known for its commitment to excellence and high-quality global service.
Medpass International
Acquisition in 2020
MedPass International SAS, based in Paris, France, is a leading European medical device contract research organization (CRO) and consultancy specializing in regulatory and reimbursement services. Founded in 1991, the company provides a comprehensive array of strategic consulting, regulatory affairs, clinical operations, biometric services, and legal representation, tailored to meet the specific needs of clients worldwide. MedPass supports the entire lifecycle of medical device development, from preclinical stages through to post-marketing, facilitating the advancement of innovative medical technologies. As of January 2020, MedPass operates as a subsidiary of ICON Public Limited Company.
Accellacare
Acquisition in 2019
Accellacare focuses on conducting clinical trials to evaluate the safety and effectiveness of new medications. The organization, formerly known as MeDiNova Research, offers comprehensive clinical trial services to the pharmaceutical, biotechnology, and medical device industries. By leveraging its network for site feasibility and central process management, Accellacare facilitates faster study initiation. Additionally, the company emphasizes patient care and engagement, utilizing a dedicated team to identify and recruit suitable participants. Their extensive patient database and targeted recruitment campaigns contribute to higher enrollment rates, enhancing the overall efficiency of the clinical trial process.
MolecularMD
Acquisition in 2019
MolecularMD, established in 2005, specializes in developing and commercializing molecular diagnostics for oncology. Based in Portland, Oregon, with a presence in Cambridge, Massachusetts, the company offers a range of services including assay design, clinical trial support, regulatory planning, and FDA submission services. MolecularMD's tests enable appropriate patient selection and monitoring for molecularly targeted cancer therapies, using both established and innovative technologies to ensure highly sensitive, reliable results. The company was founded by renowned oncologist Brian Druker and entrepreneur Sheridan G. Snyder, and operates as a subsidiary of ICON Laboratory Services Inc.
Mapi
Acquisition in 2017
Mapi, established in 1974, specializes in patient-centered research, serving academia, life science researchers, and pharmaceutical companies. It offers real-world evidence and post-approval research services, along with consulting expertise and publications. Mapi uniquely engages with the entire patient ecosystem, including healthcare providers, patient communities, payers, and regulators, driving the industry towards patient-centered research for nearly four decades.
Clinical Research Management
Acquisition in 2016
ClinicalRM is a full-service Contract Research Organization specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs and devices. The organization helps customers get their products to market faster with a wide array of research, regulatory and sponsor services within the U.S. and around the globe. From international partnerships and affiliations to government relations and local alliances, ClinicalRM delivers a synergy in the global market with projects spanning the government, academic and commercial marketplaces. The company has a distinct ability to provide boots-on-the-ground and rapid response efforts to global health crises.
PMG Research
Acquisition in 2015
PMG Research, Inc. is a clinical research organization based in Winston-Salem, North Carolina, specializing in conducting clinical trials across various therapeutic areas, including asthma, COPD, type 2 diabetes, cardiovascular diseases, and more. Founded in 1979, PMG Research operates a network of facilities located in multiple cities across the United States, including Tennessee, South Carolina, and Illinois. The organization has successfully conducted over 7,700 research studies for numerous pharmaceutical sponsors and contract research organizations (CROs), demonstrating extensive experience in all phases of clinical trials. By providing exceptional services tailored to the needs of its sponsors and participants, PMG Research plays a vital role in advancing medical research and treatment options. As of 2015, it operates as a subsidiary of ICON Clinical Research Limited.
MediMedia Pharma Solutions
Acquisition in 2015
MediMedia Managed Markets provides you with the best strategic expertise available in the industry. Their large staff of managed markets strategists, researchers, MDs, PharmDs, and MPHs, all proven experts in the field, will help.
Aptiv Solutions
Acquisition in 2014
Aptiv Solutions, Inc. is a clinical research organization that specializes in providing a range of clinical trial services to biotechnology and pharmaceutical companies. The company offers adaptive trial design, simulation, and execution, as well as early phase development consulting and drug development services. In addition to these offerings, Aptiv Solutions provides regulatory compliance consulting, focusing on strategy development, agency advisory, legal representation, and submission management. The organization has therapeutic expertise in oncology, cardiology, dermatology, respiratory conditions, and orphan diseases. Aptiv Solutions also develops AptivAdvantage, an integrated technology platform designed for the implementation and execution of adaptive clinical trials. Founded in 1983 and based in Reston, Virginia, the company has an additional office in Durham, North Carolina. It was formerly known as Averion International Corp. before rebranding in February 2011.
Cross Country Healthcare
Acquisition in 2013
Cross Country Healthcare is a prominent provider of staffing and workforce solutions specifically tailored for the healthcare industry. The company specializes in total talent management services, which encompass strategic workforce solutions, contingent staffing, permanent placement, and advisory services to address various labor-related challenges. It operates primarily through two business segments: the nurse and allied staffing segment, which accounts for the majority of its revenue, focuses on the temporary and permanent placement of travel and local nurses and allied health professionals, along with outsourcing services. The Physician Staffing segment supplies licensed practitioners across a wide range of specialties, including certified registered nurse anesthetists, nurse practitioners, and physician assistants. Through its comprehensive offerings, Cross Country Healthcare aims to assist healthcare organizations in effectively managing their staffing needs.
PriceSpective
Acquisition in 2012
PriceSpective is a value strategy consultancy that defines, drives, and captures value for pharmaceutical and biotechnology clients in today's complex healthcare environment. The company delivers expert guidance in integrated global pricing, reimbursement and market access strategy with its depth of experience and actively engaged senior leadership. PriceSpective is headquartered in Philadelphia with offices in London, Los Angeles, San Diego, Raleigh and Boston.
BeijingWits Medical Consulting
Acquisition in 2011
Beijing Wits Medical Consulting Company was founded in 1997. The company provides services to global and local pharmaceutical, medical device and biotechnology companies focusing on Phase I to IV Clinical studies. Beijing Wits currently has more than 100 employees, operating from 6 offices in China.
Firecrest Clinical
Acquisition in 2011
Firecrest Clinical Ltd specializes in site performance management solutions aimed at enhancing compliance and consistency for pharmaceutical companies. The company offers a range of services, including clinical investigator training and support for medical studies. By providing outsourced development services, Firecrest Clinical caters to the needs of the pharmaceutical, biotechnology, and medical device industries, helping them streamline their clinical operations and improve overall study performance.
Oxford Outcomes
Acquisition in 2011
Oxford Outcomes offers specialized services in health outcomes research and consultancy, focusing on patient reported outcomes (PRO), health economics, epidemiology, and translation and linguistic validation. The company's expertise enables it to support healthcare organizations in understanding the impact of health interventions from the patient perspective, as well as providing vital insights into economic factors and epidemiological trends. Through its comprehensive approach, Oxford Outcomes aims to enhance decision-making in healthcare by delivering high-quality research and analysis tailored to the needs of its clients.
Timaq Medical Imaging
Acquisition in 2010
Timaq Medical Imaging is a Swiss-based company that specializes in advanced imaging services tailored for pharmaceutical and biotechnology firms. The company supports the clinical trial process by providing essential imaging services that aid in the evaluation and development of medical products. Timaq's expertise is particularly valuable in the context of clinical studies, where accurate imaging is critical for assessing treatment efficacy and safety. By serving the pharmaceutical, biotech, and contract service sectors, Timaq Medical Imaging plays a significant role in enhancing the quality and reliability of clinical research involving medical imaging.
Veeda Laboratories
Acquisition in 2009
Veeda Laboratories Ltd is a specialist provider of biomarker laboratory services to global pharmaceutical and biotechnology industries.
Prevalere Life Sciences
Acquisition in 2008
Prevalere Life Sciences, Inc. is a contract research organization that specializes in providing consulting and analytical testing services compliant with Good Laboratory Practice (GLP) and current Good Manufacturing Practice (cGMP). The company offers a range of bio-analytical and immunoassay laboratory services, including chemical analysis, data analysis, and offsite staffing. Prevalere primarily serves the pharmaceutical and biotechnology sectors, delivering comprehensive support to meet the rigorous demands of these industries.
Barton & Polansky Associates
Acquisition in 2002
Barton & Polansky Associates, Inc is specialises in clinical research services for immuno-suppressant drugs.
UCT (U.S.)
Acquisition in 2000
UCT (U.S.), Inc provides central laboratory services for clinical trials to the pharmaceutical and biotechnology industries.
Pacific Research Associates
Acquisition in 2000
Pacific Research Associates, Inc is specialising in data management statistical analysis and medical and regulatory consulting.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.